Aptevo Therapeutics Inc. (APVO) Targets IND-Enabling Studies for APVO451 in 1H2027

Aptevo Therapeutics said it is optimizing trispecific candidates for scalable manufacturing and expects to begin IND—enabling studies for lead candidate APVO451 in 1H2027.Material DetailsContext by AI AnalystThis is an early-stage R&D and platform execution update, signaling progress toward clinica…